Placebo-controlled Study of Single and Multiple Ascending Doses of UDP-003 in Healthy Human Participants and Patients

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

February 25, 2025

Primary Completion Date

December 19, 2025

Study Completion Date

June 30, 2026

Conditions
Atherosclerotic Cardiovascular DiseaseAcute Coronary Syndromes
Interventions
DRUG

UDP-003

The UDP-003 finished product is clear, colourless to yellow liquid that is intended to be a sterile solution for IV bolus push administration in sterile water at a concentration of 300 mg/mL.

OTHER

Placebo

Placebo will be provided as a sterile clear, colourless solution formulated to match viscosity of the UDP-003 solution.

Trial Locations (1)

5000

RECRUITING

CMAX Clinical Research, Adelaide

Sponsors
All Listed Sponsors
collaborator

Monash University

OTHER

lead

Cyclarity Therapeutics, Inc.

INDUSTRY